AC Immune strikes up to $509 mln Alzheimer's deal with J&J
Jan 12 (Reuters) - Swiss biotech firm AC Immune said on Monday it had struck an exclusive worldwide license agreement potentially worth up to $509 million with Johnson & Johnson to develop so-called anti-Tau vaccines for Alzheimer's disease.
(Reporting by Ben Hirschler)
Terms and Privacy Policy